Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies designed to overcome mechanisms of resistance in cancer treatment. The company operates within the biotechnology and oncology drug development industries, with a strategic emphasis on precision medicines that address tumor resistance to targeted therapies. ORIC’s core value proposition centers on targeting key resistance pathways that limit the durability and effectiveness of existing cancer treatments.
Founded in 2014, ORIC Pharmaceuticals evolved from an early-stage research company into a publicly traded clinical-stage organization following its initial public offering in 2020. Since inception, the company has concentrated on building a diversified oncology pipeline aimed at genetically defined cancers, leveraging insights into tumor biology and adaptive resistance. Its positioning is differentiated by a resistance-focused development strategy rather than targeting primary oncogenic drivers alone.
Business Operations
ORIC’s business operations are organized around the research and development of small-molecule oncology therapeutics. The company does not generate commercial revenue and currently relies on capital from equity financing and strategic collaborations to fund operations. Its primary business activities include preclinical research, clinical development, and regulatory preparation for investigational cancer therapies.
The company’s pipeline has included multiple internally developed programs, with lead assets historically targeting breast cancer, prostate cancer, and other solid tumors characterized by therapeutic resistance. ORIC conducts clinical trials primarily in the United States while collaborating with contract research organizations and academic institutions globally. The company retains full or substantial rights to its core development programs and does not currently operate manufacturing facilities, instead outsourcing production to specialized third parties.
Strategic Position & Investments
ORIC’s strategic direction is centered on advancing a focused portfolio of oncology assets while maintaining capital discipline. Growth initiatives have included prioritizing lead clinical programs, discontinuing or out-licensing non-core assets, and reallocating resources toward candidates with clearer clinical differentiation. The company has periodically restructured its pipeline to align with evolving clinical data and market opportunities.
The company has entered into selective strategic partnerships to enhance development capabilities and manage risk, including licensing and collaboration agreements related to specific drug candidates. ORIC has also made targeted investments in emerging resistance-related technologies, though its strategy remains primarily internally driven rather than acquisition-led. Data inconclusive based on available public sources regarding any material joint ventures or controlling equity investments in external portfolio companies.
Geographic Footprint
ORIC Pharmaceuticals is headquartered in South San Francisco, California, a major biotechnology hub within the United States. Its executive leadership, research oversight, and corporate functions are primarily based at this location, supporting proximity to talent, academic collaborators, and industry partners.
Operationally, ORIC’s geographic footprint extends internationally through clinical trial sites, research collaborations, and third-party vendors across North America, Europe, and parts of Asia-Pacific. While the company does not maintain large physical offices outside the U.S., its development programs have a global orientation aligned with regulatory pathways and future commercialization potential in major oncology markets.
Leadership & Governance
ORIC is led by an executive team with experience in oncology drug development, clinical research, and biopharmaceutical operations. The leadership philosophy emphasizes scientific rigor, disciplined capital allocation, and a focused approach to addressing unmet needs in cancer resistance. Governance is overseen by a board of directors with backgrounds in biotechnology, medicine, and finance.
Key executives include:
- Jacob M. Chacko – President, Chief Executive Officer
- Jane S. Kim – Chief Financial Officer
- Mikhail Voskoboynik, M.D. – Chief Medical Officer
- Mark A. Goldsmith, Ph.D. – Chief Scientific Officer
- Matthew R. Sherman, J.D. – Chief Legal Officer and Corporate Secretary